Literature DB >> 16146463

The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.

A Kuitunen1, S Hiippala, E Vahtera, V Rasi, M Salmenperä.   

Abstract

BACKGROUND: Thrombin formation during cardiac surgery could result in disordered hemostasis and thrombosis. The aim of the study was to examine the effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic activity in patients undergoing cardiac surgery.
METHODS: Data were collected prospectively from 60 patients undergoing coronary artery bypass grafting using cardiopulmonary bypass (CPB). In a randomized sequence, 20 patients received aprotinin, 20 patients received tranexamic acid, and in 20 patients placebo was used.
RESULTS: Significant thrombin activity was found in all the studied patients. Thrombin generation was less in the aprotinin group than in the tranexamic acid and the placebo group (thrombin/anti-thrombin III complexes 33.7 +/- 3.6, 53.6 +/- 7.0 and 44.2 +/- 5.3 microg/l 2 h after CPB and F1 + 2 fragment 1.50 +/- 0.10, 2.37 +/- 0.37 and 2.04 +/- 0.20 nmol/l 6 h after surgery, respectively). The inhibition of fibrinolysis was significant with both anti-fibrinolytic drugs (D-dimers 0.427 +/- 0.032, 0.394 +/- 0.039 and 2.808 +/- 0.037 mg/l 2 h after CPB, respectively). The generation of d-dimers was inhibited until 16 h after CPB in the aprotinin group. The plasminogen activation was significantly less in the aprotinin group (plasmin/anti-plasmin complexes 0.884 +/- 0.095, 2.764 +/- 0.254 and 1.574 +/- 0.185 mg/l 2 h after CPB, respectively).
CONCLUSION: Thrombin formation is inevitable in coronary artery bypass surgery when CPB is used. The suppression of fibrinolytic activity, either with aprotinin or with tranexamic acid interferes with the hemostatic balance as evaluated by biochemical markers. Further investigations are needed to define the role of hemostatic activation in ischemic complications associated with cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16146463     DOI: 10.1111/j.1399-6576.2005.00809.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  8 in total

1.  The anesthetic experience of implantable left ventricular assist device insertion: a case report.

Authors:  Gahyun Kim; Young Wan Kim; Jong-Hwan Lee; Chung Su Kim; Hyun-Sung Cho; Sangmin Maria Lee; Young-Tak Lee
Journal:  Korean J Anesthesiol       Date:  2014-01-28

Review 2.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

Review 3.  Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery.

Authors:  Masahiro Ide; Daniel Bolliger; Taro Taketomi; Kenichi A Tanaka
Journal:  J Anesth       Date:  2009-12-29       Impact factor: 2.078

Review 4.  Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

Review 5.  Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.

Authors:  Katharine Ker; Phil Edwards; Pablo Perel; Haleema Shakur; Ian Roberts
Journal:  BMJ       Date:  2012-05-17

6.  Comparison of the in-vivo effect of two tranexamic acid doses on fibrinolysis parameters in adults undergoing valvular cardiac surgery with cardiopulmonary bypass - a pilot investigation.

Authors:  Zhen-Feng Zhou; Wen Zhai; Li-Na Yu; Kai Sun; Li-Hong Sun; Xiu-Fang Xing; Min Yan
Journal:  BMC Anesthesiol       Date:  2021-02-02       Impact factor: 2.217

7.  Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and ε-aminocaproic acid -- a meta-analysis of randomised and observational trials of over 30.000 patients.

Authors:  Patrick Meybohm; Eva Herrmann; Julia Nierhoff; Kai Zacharowski
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

8.  Aprotinin Inhibits SARS-CoV-2 Replication.

Authors:  Denisa Bojkova; Marco Bechtel; Katie-May McLaughlin; Jake E McGreig; Kevin Klann; Carla Bellinghausen; Gernot Rohde; Danny Jonigk; Peter Braubach; Sandra Ciesek; Christian Münch; Mark N Wass; Martin Michaelis; Jindrich Cinatl
Journal:  Cells       Date:  2020-10-30       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.